|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.97 - 33.62|
|52 Week Range||26.30 - 34.98|
|Beta (3Y Monthly)||0.46|
|PE Ratio (TTM)||21.83|
|Forward Dividend & Yield||1.07 (3.25%)|
|1y Target Est||37.90|
According to a JP Morgan study, some wealthy people are saying that it would take them at least $100,000 to give up their smartphones for just a month. Yahoo Finance’s Julia La Roche, Dan Roberts, Myles Udland, and Melody Hahm discuss these results.
Venture capitalist Jim Breyer, the CEO of Breyer Capital, speaks with Yahoo Finance's Julia La Roche about investing in artificial intelligence.
Nassim Nicholas Taleb, the best-selling author of "The Black Swan," speaks to Yahoo Finance's Julia La Roche at the 2019 SALT Conference in Las Vegas.
Award-winning entertainment reporter Maria Menounos talks to Yahoo Finance's Julia La Roche about the future of entertainment television.
Walmart is out with its quarterly earnings, beating expectations. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Julia La Roche discuss.
Walmart announces next-day shipping for nearly 200,000 products. It's rolling out in Phoenix, Las Vegas and Southern California first. Yahoo Finance's Julia La Roche and Seana Smith discuss.
China's leading streaming music provider beat Wall St's estimate on earnings, but revenue growth of 39% fell short of expectations. Plus an executive shakeup is worrying investors. Meanwhile, investors watching closely at Alibaba's earnings out tomorrow. Yahoo Finance's Julia La Roche joins Seana Smith.
Walmart is ramping up its competition against Amazon, and announced that it’s debuting a one-day delivery service in select markets. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, Julia La Roche break down the details.
Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.
Roche Holding AG (RHHBY) has climbed 2.4% over the last week, 0.5% over the past month, 5.7% so far this year, 17.6% over the last 52 weeks and 5.3% over the past three years through May 20. Warning! GuruFocus has detected 3 Warning Signs with RHHBY. Currently, the company is paying an annual dividend of $1.07 per common share, which, based on the closing share price on May 20, leads to a forward dividend yield of 3.27% versus the industry median of 1.66%.
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers ...
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase ...
– Phase I/II study of entrectinib, an investigational medicine, showed responses in all pediatric tumor types harboring neurotrophic tyrosine receptor kinase , ROS1 or anapla
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Venclexta® (venetoclax) in combination with Gazyva® (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). “Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard of care,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development.
AstraZeneca (ZN) needs a blockbuster to justify its nearly $7 billion investment for a share of Japan-based Daiichi Sankyo's (TSE:4568) drug to treat a type of breast cancer. Warning! GuruFocus has detected 5 Warning Signs with AZN. The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with another drug combination.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...
Swiss drugmaker Roche is pushing back its $4.3 billion (3.3 billion pounds) takeover offer for gene therapy specialist Spark Therapeutics for a third time in recent months, this time until June 14, as a U.S. regulatory review of the deal drags on. Roche and Spark are now due to refile their premerger notification on May 23, "in order to provide the government with additional time," the companies said in a joint statement on Tuesday. Roche has said the Federal Trade Commission (FTC) needed even more time to complete its review.
OTCQX: RHHBY) today announced the CE-IVD launch of the cobas® MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA. This assay is part of the mycobacteria test menu that includes the cobas® MTB and cobas® MAI tests for use on the cobas® 6800/8800 Systems.